Brainstorm Cell Therapeutics Ownership | Who Owns Brainstorm Cell Therapeutics?


OverviewRevenueFinancialsChartTranscripts

Brainstorm Cell Therapeutics Ownership Summary


Brainstorm Cell Therapeutics is owned by 15.20% institutional investors, 9.04% insiders, and 75.76% retail investors. Armistice capital is the largest institutional shareholder, holding 12.23% of BCLI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.33% of its assets in Brainstorm Cell Therapeutics shares.

BCLI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBrainstorm Cell Therapeutics15.20%9.04%75.76%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Armistice capital7.92M12.23%$2.68M
Vanguard group1.51M2.33%$511.35K
Geode capital management484.29K0.75%$163.99K
Blackrock386.41K0.60%$130.80K
Liberty wealth management340.15K0.53%$115.00K
Weaver consulting group234.36K0.36%$79.33K
State street117.26K0.18%$39.69K
Northern trust112.36K0.17%$38.03K
Raymond james & associates111.28K0.17%$37.67K
Two sigma securities102.02K0.16%$34.53K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Armistice capital7.92M0.03%$2.68M
Weaver consulting group234.36K0.03%$79.33K
Liberty wealth management340.15K0.02%$115.00K
Saxony capital management12.95K0.00%$4.38K
Jmac enterprises65.43K0.00%$22.15K
Virtu financial49.59K0.00%$17.00K
Activest wealth management7.08K0.00%$2.40K
Tower research capital llc (trc)86.58K0.00%$29.35K
Two sigma securities102.02K0.00%$34.53K
Institutional & family asset management6.00K0.00%$2.03K

Top Buyers

HolderShares% AssetsChange
Armistice capital7.92M0.03%7.92M
Geode capital management484.29K-127.24K
Vanguard group1.51M-109.65K
Two sigma securities102.02K0.00%102.02K
Tower research capital llc (trc)86.58K0.00%75.57K

Top Sellers

HolderShares% AssetsChange
Abner herrman & brock---145.50K
Gsa capital partners llp---111.23K
Blackrock386.41K--102.90K
Ikarian capital---90.24K
Kingswood wealth advisors---81.05K

New Positions

HolderShares% AssetsChangeValue
Armistice capital7.92M0.03%7.92M$2.68M
Two sigma securities102.02K0.00%102.02K$34.53K
Lpl financial10.05K-10.05K$3.40K
Activest wealth management7.08K0.00%7.08K$2.40K
Northwestern mutual wealth management161.00-161.00$55.00

Sold Out

HolderChange
Mark sheptoff financial planning-100.00
Corecap advisors-133.00
Bnp paribas arbitrage, snc-364.00
St germain d j-500.00
Cranbrook wealth management-1.00K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202437-26.00%10,822,353-10.37%154.37%10-52.38%9-
Jun 30, 2024504.17%12,075,121210.89%1851.82%2175.00%9-18.18%
Mar 31, 202448-4.00%3,884,1112.17%57.70%12-29.41%11-8.33%
Dec 31, 202350-12.28%3,801,493-17.96%88.05%17-32.00%12-
Sep 30, 202357-10.94%4,633,812-16.75%105.33%25-12-7.69%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv70.73K1.33%7.00
Fidelity Extended Market Index436.04K0.55%101.84K
Vanguard Institutional Extnd Mkt Idx Tr26.73K0.50%2.00
Fidelity Series Total Market Index100.49K0.13%54.53K
NT Ext Equity Mkt Idx Fd - L79.81K0.10%-
BlackRock Extended Equity Market K62.75K0.08%-27.00
Fidelity Nasdaq Composite Index48.73K0.06%-
Fidelity Total Market Index47.81K0.06%-
Vanguard Instl Ttl Stck Mkt Idx Tr33.75K0.04%-
NT Ext Equity Mkt Idx Fd - NL30.05K0.04%-

Recent Insider Transactions


DateNameRoleActivityValue
Oct 01, 2024Lebovits Chaim President & CEOBuy$6.29K
Sep 30, 2024Lebovits Chaim President & CEOBuy$5.02K
May 28, 2024Lebovits Chaim President & CEOBuy$7.77K
May 21, 2024Lebovits Chaim President & CEOBuy$14.47K
May 22, 2024Lebovits Chaim President & CEOBuy$16.00K

Insider Transactions Trends


DateBuySell
2024 Q41-
2024 Q311
2024 Q211-
2024 Q1--
2023 Q31-

BCLI Ownership FAQ


Who Owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics shareholders are primarily institutional investors at 15.20%, followed by 9.04% insiders and 75.76% retail investors. The average institutional ownership in Brainstorm Cell Therapeutics's industry, Biotech Stocks , is 47.04%, which Brainstorm Cell Therapeutics falls below.

Who owns the most shares of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics’s largest shareholders are Armistice capital (7.92M shares, 12.23%), Vanguard group (1.51M shares, 2.33%), and Geode capital management (484.28K shares, 0.75%). Together, they hold 15.31% of Brainstorm Cell Therapeutics’s total shares outstanding.

Does Blackrock own Brainstorm Cell Therapeutics?

Yes, BlackRock owns 0.60% of Brainstorm Cell Therapeutics, totaling 386.41K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 130.8K$. In the last quarter, BlackRock decreased its holdings by -103K shares, a -21.03% change.

Who is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested?

Armistice capital is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.03% of its assets in 7.92M Brainstorm Cell Therapeutics shares, valued at 2.68M$.

Who is the top mutual fund holder of Brainstorm Cell Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Brainstorm Cell Therapeutics shares, with 1.33% of its total shares outstanding invested in 70.73K Brainstorm Cell Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools